Treatment of erectile dysfunction with sildenafil

被引:79
作者
Marks, LS
Duda, C
Dorey, FJ
Macairan, ML
Santos, PB
机构
[1] Urol Sci Res Fdn, Culver City, CA 90232 USA
[2] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA
[3] Univ Calif Los Angeles, Sch Med, Dept Biostat, Los Angeles, CA USA
关键词
D O I
10.1016/S0090-4295(98)00525-1
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To determine the efficacy of sildenafil for the treatment of erectile dysfunction (ED) in a clinical practice setting; to evaluate the correlation between patient and partner perceptions of treatment outcomes; and to assess the relation between the severity of ED and response to treatment. Methods, Among the first 100 men to receive sildenafil in a urology practice setting, 74 (mean +/- SD age 64 +/- 11 years) completed a validated sexual function questionnaire (International Index of Erectile Function [IIEF]) before and after a 4 to 6-week treatment period. A modified version of the same questionnaire was independently completed by partners. ED was categorized into a severity class of I to IV. Results. Sildenafil treatment improved erections by 71% to 95%, according to responses in key IIEF questions 3 and 4. Overall, 57 (77%) of 74 patients desired to continue treatment after the test period. Patient score on the IIEF was correlated with partner score on the modified questionnaire before and after treatment (r = 0.67 to 0.81, P < 0.01). IIEF scores were reflected in a simple severity classification system. Men with the best presentation of erections (severity class I) exhibited the best responses to sildenafil, whereas men with no erections (severity class IV) were much less likely to respond to the drug and desire continuation of treatment (P <0.01). Patients with a radical prostatectomy were relatively refractory to sildenafil. except for 2 of 5 who had undergone a nerve-sparing operation. Conclusions. In clinical practice, sildenafil is an effective treatment of ED, according to partner-validated questionnaire responses; and the results of treatment are predictable with an ED severity classification system. UROLOGY 53: 19-24, 1999. (C) 1999, Elsevier Science inc. All rights reserved.
引用
收藏
页码:19 / 24
页数:6
相关论文
共 7 条
  • [1] DROLLER MJ, 1993, JAMA-J AM MED ASSOC, V270, P83
  • [2] Oral sildenafil in the treatment of erectile dysfunction
    Goldstein, I
    Lue, TF
    Padma-Nathan, H
    Rosen, RC
    Steers, WD
    Wicker, PA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (20) : 1397 - 1404
  • [3] Erectile dysfunction: Therapy health outcomes
    Jackson, SE
    Lue, TF
    [J]. UROLOGY, 1998, 51 (06) : 874 - 882
  • [4] Treatment of men with erectile dysfunction with transurethral alprostadil
    PadmaNathan, H
    Hellstrom, WJG
    Kaiser, FE
    Labasky, RF
    Lue, TF
    Nolten, WE
    Norwood, PC
    Peterson, CA
    Shabsigh, R
    Tam, PY
    Place, VA
    Gesundheit, N
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (01) : 1 - 7
  • [5] The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction
    Rosen, RC
    Riley, A
    Wagner, G
    Osterloh, IH
    Kirkpatrick, J
    Mishra, A
    [J]. UROLOGY, 1997, 49 (06) : 822 - 830
  • [6] Sildenafil: medical advance or media event?
    Rosen, RC
    [J]. LANCET, 1998, 351 (9116) : 1599 - 1600
  • [7] MUSE therapy: Preliminary clinical observations
    Werthman, P
    Rajfer, J
    [J]. UROLOGY, 1997, 50 (05) : 809 - 811